Sabri Hassouna, Marek Hozman, Barbora Bacova, Ivana Fiserova, Jana Vesela, Petr Waldauf, Dalibor Herman, Pavel Osmancik
{"title":"Markers of apoptosis and cardiac necrosis during the acute phase of catheter ablation using radiofrequency and pulsed-field energy.","authors":"Sabri Hassouna, Marek Hozman, Barbora Bacova, Ivana Fiserova, Jana Vesela, Petr Waldauf, Dalibor Herman, Pavel Osmancik","doi":"10.1080/1354750X.2025.2536009","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The mechanism of cell death during pulsed-field ablation (PFA) appears distinct from thermal energy sources like radiofrequency ablation (RFA), with apoptosis often cited as the primary cause in PFA. This study aimed to clarify the mechanism by comparing markers of necrosis and apoptosis after PFA and RFA.</p><p><strong>Methods and results: </strong>Patients undergoing pulmonary vein isolation (PVI) for atrial fibrillation were randomized to receive either PFA (Farapulse, Boston Scientific) or RFA (CARTO Smart Touch, Biosense Webster). Myocardial necrosis was assessed via troponin I, and apoptosis via soluble cleaved caspase-3 and Fas ligand, measured pre- and one day post-ablation.</p><p><strong>Results: </strong>Sixty-five patients were enrolled (PFA: <i>n</i> = 33; RFA: <i>n</i> = 32), with comparable baseline characteristics. One day post-procedure, troponin I levels were significantly higher in the PFA group (median 10,102 ng/L; IQR 8,272-14,207) versus the RFA group (1,006 ng/L; IQR 603-1,433). No post-procedure increase in caspase-3 or Fas ligand was observed in the PFA group, and no differences in apoptotic markers were found between groups.</p><p><strong>Conclusion: </strong>In vivo, apoptosis does not appear to be the predominant mechanism of cardiomyocyte death following PFA for atrial fibrillation.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-5"},"PeriodicalIF":1.9000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1354750X.2025.2536009","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The mechanism of cell death during pulsed-field ablation (PFA) appears distinct from thermal energy sources like radiofrequency ablation (RFA), with apoptosis often cited as the primary cause in PFA. This study aimed to clarify the mechanism by comparing markers of necrosis and apoptosis after PFA and RFA.
Methods and results: Patients undergoing pulmonary vein isolation (PVI) for atrial fibrillation were randomized to receive either PFA (Farapulse, Boston Scientific) or RFA (CARTO Smart Touch, Biosense Webster). Myocardial necrosis was assessed via troponin I, and apoptosis via soluble cleaved caspase-3 and Fas ligand, measured pre- and one day post-ablation.
Results: Sixty-five patients were enrolled (PFA: n = 33; RFA: n = 32), with comparable baseline characteristics. One day post-procedure, troponin I levels were significantly higher in the PFA group (median 10,102 ng/L; IQR 8,272-14,207) versus the RFA group (1,006 ng/L; IQR 603-1,433). No post-procedure increase in caspase-3 or Fas ligand was observed in the PFA group, and no differences in apoptotic markers were found between groups.
Conclusion: In vivo, apoptosis does not appear to be the predominant mechanism of cardiomyocyte death following PFA for atrial fibrillation.
期刊介绍:
The journal Biomarkers brings together all aspects of the rapidly growing field of biomarker research, encompassing their various uses and applications in one essential source.
Biomarkers provides a vital forum for the exchange of ideas and concepts in all areas of biomarker research. High quality papers in four main areas are accepted and manuscripts describing novel biomarkers and their subsequent validation are especially encouraged:
• Biomarkers of disease
• Biomarkers of exposure
• Biomarkers of response
• Biomarkers of susceptibility
Manuscripts can describe biomarkers measured in humans or other animals in vivo or in vitro. Biomarkers will consider publishing negative data from studies of biomarkers of susceptibility in human populations.